Henrijette Richter is Managing Partner at Sofinnova Partners. She joined the firm in 2014. Prior to that, she was part of the team that founded Novo Seeds in 2007, and as an Investment Director, was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris). Henrijette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts. Her investments and board involvements include Asceneuron, Delinia (sold to Celgene), iOmx Therapeutics, Muna Therapeutics, Nodthera, Nitrome Biosciences, and Twentyeight-Seven Therapeutics.